CELC Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-1.042

+22.59%

-1.038

+20.74%

-1.092

+4.97%

Estimates Revision

The market is revising No Change the revenue expectations for Celcuity Inc. (CELC) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 117.32%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-1.44%

In Past 3 Month

Stock Price

Go Up

+117.32%

In Past 3 Month

9 Analyst Rating

Wall Street analysts forecast CELC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CELC is 98.43 USD with a low forecast of 70.00 USD and a high forecast of 115.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

70.00

Averages

98.43

High

115.00

Current: 0.000

Low

70.00

Averages

98.43

High

115.00

Wells Fargo

initiated

$126

2025-12-12

Reason

Wells Fargo

Price Target

$126

2025-12-12

initiated

Reason

As previously reported, Wells Fargo initiated coverage of Celcuity with an Overweight rating and $126 price target. The firm believes the upcoming VIKTORIA-1 PI3KCA mutant readout is largely de-risked by the wild-type readout and Phase 1. The current stock price doesn't reflect gedatolisib's market opportunity in breast cancer and metastatic castration-resistant prostate cancer is a free call option at these levels, Wells adds.

Wells Fargo

initiated

$126

2025-12-12

Reason

Wells Fargo

Price Target

$126

2025-12-12

initiated

Reason

Wells Fargo initiated coverage of Celcuity with an Overweight rating and $126 price target.

Wolfe Research

Outperform

initiated

$110

2025-11-17

Reason

Wolfe Research

Price Target

$110

2025-11-17

initiated

Outperform

Reason

Wolfe Research initiated coverage of Celcuity with an Outperform rating and $110 price target. Fresh off a Phase 3 win for gedatolisib in second-line PIK3CA-wt breast cancer, the firm sees additional upside as the PIK3CA-mt readout looks "primed to deliver next year," the analyst tells investors. The firm views Celcuity as "a top-tier acquisition opportunity for big pharma," the analyst added.

H.C. Wainwright

Buy -> Neutral

downgrade

$77 -> $94

2025-11-17

Reason

H.C. Wainwright

Price Target

$77 -> $94

2025-11-17

downgrade

Buy -> Neutral

Reason

H.C. Wainwright downgraded Celcuity to Neutral from Buy with a price target of $94, up from $77. The shares look "priced for perfection," the analyst tells investors in a research note. The firm says Celcuity shares have appreciated 608% year-to-date. At current levels, there is more downside risk than upside, contends H.C. Wainwright.

Stifel

Buy

upgrade

$68 -> $115

2025-11-13

Reason

Stifel

Price Target

$68 -> $115

2025-11-13

upgrade

Buy

Reason

Stifel raised the firm's price target on Celcuity to $115 from $68 and keeps a Buy rating on the shares. Following the Q3 call and the firm's recent fireside chat with CEO Brian Sullivan, the firm is increasing its price target based on updated VIKTORIA-1 U.S. sales and odds of success estimates, the analyst tells investors.

Craig-Hallum

Chase Knickerbocker

Buy

maintain

$96 -> $108

2025-11-13

Reason

Craig-Hallum

Chase Knickerbocker

Price Target

$96 -> $108

2025-11-13

maintain

Buy

Reason

Craig-Hallum analyst Chase Knickerbocker raised the firm's price target on Celcuity to $108 from $96 and keeps a Buy rating on the shares. The firm notes adjusted EPS came in at (78c) vs Street (91c). Timelines were reiterated with the NDA for PIK3CAwt on track for Q4 and early launch prep underway. The PIK3CA-mutant cohort readout is expected in Q1 2026/Q2 2026.

Valuation Metrics

The current forward P/E ratio for Celcuity Inc (CELC.O) is -23.83, compared to its 5-year average forward P/E of -7.08. For a more detailed relative valuation and DCF analysis to assess Celcuity Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.08

Current PE

-23.83

Overvalued PE

-2.18

Undervalued PE

-11.98

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.60

Current EV/EBITDA

-21.88

Overvalued EV/EBITDA

1.71

Undervalued EV/EBITDA

-6.91

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

201.36

Current PS

586.46

Overvalued PS

829.34

Undervalued PS

-426.63

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CELC News & Events

Events Timeline

No data

News

3.5

01-08Globenewswire

Oncolytics Biotech Fortifies IP Protection, Extends Pelareorep Commercial Runway to 2044

9.5

2025-12-31NASDAQ.COM

Palvella Therapeutics Stock Soars to $114.69 Following Pipeline Developments

2.0

2025-12-19NASDAQ.COM

The $100 Club - Did You Get in Early on the Triple-Digit Surge of ABVX, NUTX, BLTE…?

People Also Watch

Frequently Asked Questions

What is Celcuity Inc (CELC) stock price today?

The current price of CELC is 107.51 USD — it has increased 2.71 % in the last trading day.

What is Celcuity Inc (CELC)'s business?

Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.

What is the price predicton of CELC Stock?

What is Celcuity Inc (CELC)'s revenue for the last quarter?

Celcuity Inc revenue for the last quarter amounts to -42.85M USD, increased 42.55 % YoY.

What is Celcuity Inc (CELC)'s earnings per share (EPS) for the last quarter?

Celcuity Inc. EPS for the last quarter amounts to -44913000.00 USD, increased 117.89 % YoY.

What changes have occurred in the market's expectations for Celcuity Inc (CELC)'s fundamentals?

How many employees does Celcuity Inc (CELC). have?

Celcuity Inc (CELC) has 87 emplpoyees as of January 10 2026.

What is Celcuity Inc (CELC) market cap?

Today CELC has the market capitalization of 4.97B USD.